Transfusion-Transmitted Infection in Hemophilia in Developing Countries

Thynn Yee; Christine A. Lee

doi:10.1055/s-2005-922224

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2005; 31(5): 527-537
DOI: 10.1055/s-2005-922224

Transfusion-Transmitted Infection in Hemophilia in Developing Countries

Thynn Yee¹ , Christine A. Lee¹ ^, ²

¹Haemophilia Centre and Haemostasis Unit, The Royal Free Hospital, London, United Kingdom
²Professor Haemophilia Centre and Haemostasis Unit, The Royal Free Hospital, London, United Kingdom

Abstract

ABSTRACT

Treatment of patients with bleeding disorders (especially those with hemophilia) with blood products has been associated with infections with blood-borne viruses. Of these, hepatitis B and C viruses (HBV and HCV, respectively) and the human immunodeficiency virus (HIV) have created major health problems. Although virus-inactivation procedures have virtually eliminated these viruses from newer factor concentrates since 1985, the risk remains in developing countries where there is no ready access to these concentrates. Although a few of these countries have established their own fractionation facilities and in others the respective governments make concentrates available, the large majority of countries still face the problems of blood-borne infections. HCV will invariably lead to liver damage and many hemophiliacs who were exposed to the HCV virus will succumb to cirrhosis. Only approximately 10% of hemophilic patients infected with HCV will clear the infection naturally. Coinfection with HIV shortens the life expectancy. The HIV epidemic in hemophiliacs began in the mid-1980s. Patients in developed countries were especially affected because they were predominantly treated with factor concentrates that were manufactured from thousands of blood donors. Hemophiliacs in developing countries have considerably less HIV infection, although it does exist and depends largely on the source of the plasma fractions. Progress has been made not only in the purification of factor concentrates, but also in the understanding of the HIV virus and in the development of antiretroviral treatment modalities. However, there are still several challenges in delivering antiretroviral treatment that must be addressed before the full impact of these transmitted infections is known.

KEYWORDS

Hemophilia - HBV - HCV - HIV - factor concentrates - antiretroviral treatment - developing countries

Full Text

References

REFERENCES

1 Lee C A, Phillips A, Elford J et al.. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol. 1989; 73 228-234
2 Kernoff P B, Lee C A, Karayiannis P, Thomas H C. High risk of a non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates effects of prophylactic immune serum globulin. Br J Haematol. 1985; 60 469-479
3 The Economist . Could AIDS explode in India?. Economist. 2004; (April) 17
4 Mannucci P M. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol. 1996; 9 273-290
5 Farrugia A. Safety and supply of haemophilia products: worldwide perspectives. Haemophilia. 2004; 10 327-333
6 Yee T T, Cohen B J, Pasi K J, Lee C A. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol. 1996; 93 457-459
7 Burnouf T, Radosevich M. Reducing the risk of infection from plasma products; specific preventative strategies. Blood Rev. 2000; 14 94-110
8 Srivastava A. Factor replacement therapy in haemophilia-are there models for developing countries?. Haemophilia. 2003; 9 391-396
9 Bird A, Isarangkura P, Almagro D, Gonzaga A, Srivastava A. Factor concentrates for haemophiliacs in the developing world. Haemophilia. 1998; 4 481-485
10 Chuansumrit A. Treatment of haemophilia in the developing countries. Haemophilia. 2003; 9 387-390
11 Petersen I P, Bird A R. Small pool heat treated intermediate purity factor VIII concentrate. Montreal, Canada; World Federation of Haemophilia Monograph 1997 (April): 1-4
12 WFH Global Survey 2003 .World Federation of Haemophilia. Available at: http://www.wfh.org Accessed August 5, 2005
13 Choo Q L, Kuo G, Weiner A J et al.. Isolation of a C DNA done derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244 359-362
14 Rosenberg W, Khakoo S. Epidemiology, natural history and pathophysiology. In: Pocket Reference to Hepatitis C Infection London; Science Press 2002
15 Mansour-Ghanaei F, Fallah M S, Shafaghi A et al.. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). Med Sci Monit. 2002; 8 797-800
16 Timan I S, Aulia D, Atmakusma D et al.. Some hematological problems in Indonesia. Int J Hematol. 2002; 76(suppl 1) 286-290
17 Seme K, Poljak M, Begovac J et al.. Low prevalence of hepatitis C virus infection among human immunodeficiency virus type 1-infected individuals from Slovenia and Croatia. Acta Virol. 2002; 46 91-94
18 Wharfe G, Smikle M, Dowe G et al.. Seroprevalence of hepatitis C virus in haemophiliacs in Jamacia. Hum Antibodies. 2002; 11 61-64
19 Fontes E M, Amorim L, Carvalho S M, Farah M B. Hemophilia care in the state of Rio de Janeiro, Brazil. Rev Panam Salud Publica. 2003; 13 124-128
20 Carmo R A, Oliveira G C, Guimaraes M D et al.. Hepatitis C virus infection among Brazilian hemophiliacs: a virological, clinical and epidemiological study. Braz J Med Biol Res. 2002; 35 589-598
21 Barbosa A P, Martins R M, Teles S A et al.. Prevalence of hepatitis C virus infection among hemophiliacs central Brazil. Mem Inst Oswaldo Cruz. 2002; 97 643-644 , errata August 30, 2002
22 Jarvis L M, Watson H G, McOmish F et al.. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis. 1994; 170 1018-1022
23 Jarvis L M, Ludlam C A, Simmonds P. Hepatitis C virus genotypes in multi-transfused individuals. Haemophilia. 1995; 1(suppl 4) 3-7
24 Eyster M E, Sherman K E, Goedert J J, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotype among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis. 1999; 179 1062-1069
25 Sheng L, Willems M, Peenlinck K, Vermylen J, Yap S H. Hepatitis C virus genotypes in Belgian haemophiliacs. J Med Virol. 1995; 45 211-214
26 Suou T, Kawatani T, Nishikawa K et al.. High prevalence of hepatitis C virus genotype 1a in Japanese hemophiliacs. Int Hepatol Commun. 1996; 4 301-304
27 Mauser-Bunschoten E P, Bresters D, Van Drimmelen A A et al.. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol. 1995; 45 241-246
28 Yee T T, Griffoen A, Sabin C A, Dusheiko G, Lee C A. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut. 2000; 47 845-851
29 Franchini M, Rossetti G, Tagliferri A et al.. The natural history of chronic hepatitis C in a cohort of HIV negative Italian patients with hereditary bleeding disorders. Blood. 2001; 98 1836-1841
30 Darby S C, Ewart D W, Giangrande P LF et al.. Mortality from liver cancer and liver disease in haemophilic men and boys in the UK given blood products contaminated with hepatitis C. Lancet. 1997; 350 1425-1431
31 Wilde J T. HIV and HCV coinfection in haemophilia. Haemophilia. 2004; 10 1-8
32 Ragni M V, Belle S H. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with haemophilia and hepatitis C virus infection. J Infect Dis. 2001; 183 1112-1115
33 Quintana M, Villar A, Jimenez V et al.. Progression of HIV infection and mortality by hepatitis infection in patients with haemophilia over 20 years. Haemophilia. 2003; 9 605-612
34 Eyster M E, Fried M W, Di Bisceglie A M, Goedert J J. Increasing hepatitis C virus RNA levels in haemphiliacs: relationship to human immunodefiency virus infection and liver disease. Blood. 1994; 84 1020-1023
35 Fauci A S, Schnittman S M, Poli G, Koenig S, Pantaleo G. Immunopathogenetic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991; 114 678-693
36 Sabin C A, Telfer P, Phillips A N, Bhagani S, Lee C A. The association between hepatitis C virus genotype and human immuno-deficiency virus disease progression in a cohort of haemophilic men. J Infect Dis. 1997; 175 164-168
37 Centers for Disease Control . Pneumocystis carinii pneumonia among persons with haemophilia. MMWR. 1982; 31 365
38 Bottiger B, Blombäck M, Berntorp E et al.. HIV-serology and Lymphocyte subsets in relation to therapy and clinical development in haemophiliacs. Eur J Haematol. 1988; 41 459-466
39 Melbye M, Froebel K S, Madhok R et al.. HTLV-III seropositivity in European haemophiliacs receiving factor VIII concentrate imported from the USA. Lancet. 1984; 2 1444-1446
40 Goedert J J, Sarngadharan M G, Eyster M E et al.. Antibodies reactive with human T cell leukemia viruses in the serum of haemophiliacs receiving factor VIII concentrate. Blood. 1985; 65 492-495
41 Erfle V, Hehlmann R, Mellert W et al.. Prevalence of antibodies to HTLV-III in AIDS risk groups in West Germany. Cancer Res. 1985; 45(suppl) 4627s-4629s
42 Darby S C, Rizza C R, Doll R et al.. Seropositivity for HIV and incidence of AIDS and AIDS related complex in UK haemophilics: report on behalf of the Directors of haemophilia centres in the UK. BMJ. 1989; 298 1064-1068
43 Haemophilia Study Group . Haemophilia, HIV infection and blood transfusion in Belgium. Acta Clin Belg. 1988; 39 44-48
44 Evensen S A, Ulstrup J, Skaug K et al.. HIV infection in Norwegian haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors. Eur J Haematol. 1987; 39 44-48
45 Rosendaal F R, Smit C, Varekamp I et al.. AIDS and haemophilia: a study among Dutch haemophiliacs on the psychological impact of the AIDS threat, the prevalence of HIV antibodies and the adoption of measures to prevent HIV infection. Haemostasis. 1988; 18 73-82
46 Rasi V, Ikkala E, Myllyla G, Nevanlinna H R. Low prevalence of antibodies against human immunodeficiency virus in Finnish haemophiliacs. Vox Sang. 1991; 60 159-161
47 Allain J P. Prevalence of HTLV-III/LAV antibodies in patients with haemophilia and their sexual partners in France. N Engl J Med. 1986; 315 517-518
48 Singhvi A, Pulimood R B, John T J et al.. The prevalence of markers for hepatitis B and human immunodeficiency viruses, malarial parasites, and microfilaria in blood donors in a large hospital in south India. J Trop Med Hyg. 1990; 93 178
49 Karimi M, Yarmohammadi H, Ardeshiri R, Yarmohammadi H. Inherited coagulation disorders in southern Iran. Haemophilia. 2002; 8 740-744
50 Hosseinipour M C, Kazembe P N, Sanne I M, van der Horst C M. Challenges in delivering antiretroviral treatment in resource poor countries. AIDS. 2002; 16(suppl 4) S177-187
51 Sherring A, Bergeron M, Mandy F. Comparison of two alternative CD4 T-cell enumerating methods suitable for laboratories with low volume immunophenotyping in resource-poor settings. Program and abstracts of the XIV International AIDS Conference July 7-12, 2002 Barcelona, Spain;
52 WHO .Scaling up antiretroviral therapy in resource limited settings: Guidelines for a public health approach: Executive summary. Geneva; World Health Organization 2002
53 Qazi S, Vareldzis B, Giaquinto C. HIV treatment for children: applying the 2002 WHO interim ARV treatment guidelines for resource poor settings. Program and abstracts or the XIV International AIDS Conference July 7-12, 2002 Barcelona, Spain;
54 Yeni P G, Hammer S M, Carpenter C C et al.. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002; 288 222-235
55 Paterson D L, Swindells S, Mohr J et al.. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133 21-30
56 Adje C, Cheingsong R, Roels T H et al.. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Lvoire. J Acquir Immune Defic Syndr. 2001; 26 501-506
57 Vergne L, Malonga-Mouellet G, Mistoul I et al.. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines in ARV use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr. 2002; 29 165-168
58 James JS. Treatment in developing countries: new UNAIDS pilot program. AIDS Treat News. 1997; 283 7
59 Weidle P J, Malamba S, Mwebaze R et al.. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients response, survival, and drug resistance. Lancet. 2002; 360 34-40
60 From Durban to Barcelona .Overcoming the treatment deficit. Available at: http://www.doctorswithoutborders.org/publications/reports/2002/fdtb_07-2002.pdf Accessed August 5, 2005

Christine A LeeM.D.

Haemophilia Centre and Haemostasis Unit, The Royal Free Hospital

Pond St., Hampstead, London NW3 3QG, United Kingdom

Email: Christine.lee@royalfree.uhs.uk